MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ
5.97
+0.10
+1.70%
Pre Market: 5.97 0 0.00% 07:10 04/08 EDT
OPEN
5.86
PREV CLOSE
5.87
HIGH
6.02
LOW
5.78
VOLUME
9
TURNOVER
0
52 WEEK HIGH
6.45
52 WEEK LOW
2.455
MARKET CAP
475.64M
P/E (TTM)
-3.0726
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVIR last week (0330-0403)?
Weekly Report · 2d ago
Weekly Report: what happened at AVIR last week (0323-0327)?
Weekly Report · 03/30 10:11
Weekly Report: what happened at AVIR last week (0316-0320)?
Weekly Report · 03/23 10:07
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Benzinga · 03/18 12:59
Weekly Report: what happened at AVIR last week (0309-0313)?
Weekly Report · 03/16 10:07
Morgan Stanley Keeps Their Hold Rating on Atea Pharmaceuticals (AVIR)
TipRanks · 03/11 12:36
Atea Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 03/09 16:10
Atea Pharmaceuticals Price Target Raised to $10.00/Share From $6.00 by Evercore ISI Group
Dow Jones · 03/09 16:10
More
About AVIR
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

Webull offers Atea Pharmaceuticals Inc stock information, including NASDAQ: AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.